SELECT BIOMARKER ANALYSES OF COMPLETELY RESECTED NSCLC TUMORS FROM ENROLLED PATIENTS IN AN ADJUVANT ERLOTINIB (TARCEVA®) CLINICAL TRIAL (RADIANT)

被引：0
|
作者：
Richardson, Frank [1 ]
Richardson, Katherine [2 ]
Young, David [3 ]
Sennello, Regina [4 ]
Horan, Julie [5 ]
Davies, Angela [4 ]
Crino, Lucio [6 ]
Krzakowski, Maciej [7 ]
Hoffman, Philip [8 ]
Chang, Gee Chen [9 ]
O'Orian, Mary [10 ]
Kim, Hoon-Kyo [11 ]
Cho, Eun Kyung [12 ]
机构：
[1] Osi Pharmaceut, Samm, Farmingdale, NY USA
[2] Transgenomic, Omaha, NE USA
[3] Flagship Biosci, Boulder, CO USA
[4] Osi Pharmaceut, Farmingdale, NY USA
[5] Novella Clin, Durham, NC USA
[6] Osped Perugia, Perugia, Italy
[7] Maria Sklodowska Curie Inst Oncol, Warsaw, Poland
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Taichung Vet Gen Hosp, Taichung, Taiwan
[10] Royal Marsden Hosp, London, England
[11] Catholic Univ Korea, St Vincent Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Hosp, Songnam, Gyeonggi Do, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Biomarkers; RADIANT; NSCLC Adjuvant; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S397 / S398
页数：2
相关论文
共 50 条
  • [1] Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib (Tarceva®) clinical trial (RADIANT)
    Richardson, Frank
    Richardson, Katherine
    Sennello, Regina
    Young, David
    Choporov, Sergey
    Gorbunova, Vera
    Heo, Dae-Seog
    Milanowski, Janusz
    Tsai, Chun Ming
    Altorki, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S332 - S333
  • [2] Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)
    Richardson, F.
    Richardson, K.
    Sennello, G.
    Young, D.
    Orlov, S.
    Papai-Szekely, Z.
    Keshavjee, S.
    Kim, J.
    Cerfolio, R.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Janne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel Botelho
    Rosovsky, Rachel Pam Greenerger
    Wakelee, Heather A.
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Temel, Jennifer S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Lanuti, Michael
    Lynch, Thomas James
    Kris, Mark G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial
    Spira, A. I.
    Ardizzoni, A.
    Barlesi, F.
    Cho, B. C.
    De Marchi, P.
    Goto, Y.
    Kowalski, D.
    Lu, S.
    Paz-Ares, L.
    Spigel, D. R.
    Thomas, M.
    Leung, M.
    Baum, J.
    Zhou, W.
    Portella, S.
    Yang, J. Chih-Hsin
    Garon, E. B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S25 - S25
  • [5] Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.
    Shepherd, Frances A.
    Altorki, Nasser K.
    Eberhardt, Wilfried Ernst Erich
    O'Brien, Mary E. R.
    Spigel, David R.
    Crino, Lucio
    Tsai, Chun-Ming
    Kim, Joo-Hang
    Cho, Eun Kyung
    Szczesna, Aleksandra
    Burghuber, Otto
    Hoffman, Philip C.
    Keshavjee, Shaf
    Orlov, Sergey
    Serwatowski, Piotr
    Wang, Jiuzhou
    Foley, Margaret A.
    Horan, Julie D.
    Richardson, Frank C.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results
    Altorki, N. K.
    O'brien, M. E. R.
    Eberhardt, W. E. E.
    Richardson, F. C.
    Wang, J.
    Foley, M. A.
    Horan, J. D.
    Shepherd, F. A.
    Kelly, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S3
  • [7] The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
    Pennell, N. A.
    Neal, J. W.
    Govindan, R.
    Janne, P. A.
    Evans, T. L.
    Costa, D. B.
    Rosovsky, R. P. G.
    Lanuti, M.
    Azzoli, C. G.
    Sequist, L. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Santoro, Armando
    Ross, Paul
    Gane, Edward
    Vogel, Arndt
    Jeffers, Michael
    Meinhardt, Gerold
    Pena, Carol E. A.
    CLINICAL CANCER RESEARCH, 2016, 22 (19) : 4870 - 4879
  • [9] SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Jaenne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel B.
    Wakelee, Heather A.
    Heist, Rebecca S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Murthy, Sudish
    Lanuti, Michael
    Rusch, Valerie W.
    Kris, Mark G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) : 97 - +
  • [10] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
    Calvo, Virginia
    Domine, Manuel
    Sullivan, Ivana
    Gonzalez-Larriba, Jose-Luis
    Ortega, Ana Laura
    Bernabe, Reyes
    Sala, Maria Angeles
    Campos, Begona
    De Castro, Javier
    Martin-Martorell, Paloma
    Bosch-Barrera, Joaquim
    Mielgo, Xabier
    Vila, Laia
    Casal, Joaquin
    Ros, Silver
    Aguillo, Maite Martinez
    Padilla, Airam
    Sandiego, Sergio
    Machado, Jonathan Aires
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345